We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Novo Nordisk Confirms Bid for Ablynx But Faces Rejection
Read MoreHide Full Article
Novo Nordisk (NVO - Free Report) confirmed that it has made a revised offer to buy Belgian biotech company — Ablynx NV — on Dec 22, for 2.6 billion euros ($3.1 billion). This includes a total cash consideration of EUR 28.00 per share and one Contingent Value Right ('CVR') with total potential cash payments over time of up to EUR 2.50 per share. The proposal values the Belgian company about 14% more than Novo Nordisk’s first proposal, which was made on Dec 7.
On Dec 7, Novo Nordisk first offered to acquire Ablynx in a deal worth EUR 26.75 per share in cash. However, the proposal was rejected by Ablynx's board of directors on Dec 14. On Dec 22, the company made a revised offer (as discussed above) but was again turned down by Ablynx's board the next day. In fact, the board of directors of Ablynx has so far declined to engage in any discussions despite Novo Nordisk’s repeated proposals.According to Ablynx, the proposal made by Novo Nordisk is not in the best interests of the former and fundamentally undervalues the company and its strong prospects for future growth.
While Ablynx soared above 45% on Jan 8 on takeout potential, Novo Nordiskslipped 0.09% on the same day.
Shares of Novo Nordiskhave have decreased 49.9% against the industry’s gain of 16.1% in the past one year.
Nevertheless, Novo Nordisk remains optimistic about the Ablynx acquisition. It believes that Ablynx’s lead pipeline candidate, caplacizumab, which is being evaluated for the rare bleeding disorder acquired thrombotic thrombocytopenic purpura (aTTP) might complement Novo's line-up of hemophilia products.
Also, the company sees considerable opportunity in Ablynx’s other pipeline candidates and its nanobody platform.
Novo Nordisk carries a Zacks Rank #2 (Buy). Some better-ranked health care stocks are Exelixis, Inc. (EXEL - Free Report) , XOMA Corporation (XOMA - Free Report) and Sucampo Pharmaceuticals . While Exelixis and XOMA sport a Zacks Rank #1 (Strong Buy), Sucampo carries a Zacks Rank #2. You can see the complete list of today’s Zacks #1 Rank stocks here.
Exelixis’earnings per share estimates have moved up from 72 cents to 73 cents for 2018 in the last 60 days. The company delivered a positive earnings surprise in all the last four quarters, with an average beat of 572.92%. Share price of the company surged 66.7% in 2017.
XOMA’s loss per share estimates have narrowed from $1 to 42 cents for 2018 in the last 60 days. The company pulled off a positive earnings surprise in one of the last four quarters, with an average beat of 47.92%. Share price of the company skyrocketed 537.1% in 2017.
Sucampo’s earnings per share estimates have moved up from 3 cents to $1.12 for 2017 and from $1.15 to $1.19 for 2018 in the last 60 days. The company delivered a positive earnings surprise in three of the last four quarters, with an average beat of 15.63%. Share price of the company has surged 35.8% in 2017.
Zacks’ Best Private Investment Ideas
While we are happy to share many articles like this on the website, our best recommendations and most in-depth research are not available to the public.
Starting today, for the next month, you can follow all Zacks' private buys and sells in real time. Our experts cover all kinds of trades… from value to momentum . . . from stocks under $10 to ETF and option moves . . . from stocks that corporate insiders are buying up to companies that are about to report positive earnings surprises. You can even look inside exclusive portfolios that are normally closed to new investors.
Image: Bigstock
Novo Nordisk Confirms Bid for Ablynx But Faces Rejection
Novo Nordisk (NVO - Free Report) confirmed that it has made a revised offer to buy Belgian biotech company — Ablynx NV — on Dec 22, for 2.6 billion euros ($3.1 billion). This includes a total cash consideration of EUR 28.00 per share and one Contingent Value Right ('CVR') with total potential cash payments over time of up to EUR 2.50 per share. The proposal values the Belgian company about 14% more than Novo Nordisk’s first proposal, which was made on Dec 7.
On Dec 7, Novo Nordisk first offered to acquire Ablynx in a deal worth EUR 26.75 per share in cash. However, the proposal was rejected by Ablynx's board of directors on Dec 14. On Dec 22, the company made a revised offer (as discussed above) but was again turned down by Ablynx's board the next day. In fact, the board of directors of Ablynx has so far declined to engage in any discussions despite Novo Nordisk’s repeated proposals.According to Ablynx, the proposal made by Novo Nordisk is not in the best interests of the former and fundamentally undervalues the company and its strong prospects for future growth.
While Ablynx soared above 45% on Jan 8 on takeout potential, Novo Nordiskslipped 0.09% on the same day.
Shares of Novo Nordiskhave have decreased 49.9% against the industry’s gain of 16.1% in the past one year.
Nevertheless, Novo Nordisk remains optimistic about the Ablynx acquisition. It believes that Ablynx’s lead pipeline candidate, caplacizumab, which is being evaluated for the rare bleeding disorder acquired thrombotic thrombocytopenic purpura (aTTP) might complement Novo's line-up of hemophilia products.
Also, the company sees considerable opportunity in Ablynx’s other pipeline candidates and its nanobody platform.
Novo Nordisk A/S Price
Novo Nordisk A/S Price | Novo Nordisk A/S Quote
Zacks Rank & Key Picks
Novo Nordisk carries a Zacks Rank #2 (Buy). Some better-ranked health care stocks are Exelixis, Inc. (EXEL - Free Report) , XOMA Corporation (XOMA - Free Report) and Sucampo Pharmaceuticals . While Exelixis and XOMA sport a Zacks Rank #1 (Strong Buy), Sucampo carries a Zacks Rank #2. You can see the complete list of today’s Zacks #1 Rank stocks here.
Exelixis’earnings per share estimates have moved up from 72 cents to 73 cents for 2018 in the last 60 days. The company delivered a positive earnings surprise in all the last four quarters, with an average beat of 572.92%. Share price of the company surged 66.7% in 2017.
XOMA’s loss per share estimates have narrowed from $1 to 42 cents for 2018 in the last 60 days. The company pulled off a positive earnings surprise in one of the last four quarters, with an average beat of 47.92%. Share price of the company skyrocketed 537.1% in 2017.
Sucampo’s earnings per share estimates have moved up from 3 cents to $1.12 for 2017 and from $1.15 to $1.19 for 2018 in the last 60 days. The company delivered a positive earnings surprise in three of the last four quarters, with an average beat of 15.63%. Share price of the company has surged 35.8% in 2017.
Zacks’ Best Private Investment Ideas
While we are happy to share many articles like this on the website, our best recommendations and most in-depth research are not available to the public.
Starting today, for the next month, you can follow all Zacks' private buys and sells in real time. Our experts cover all kinds of trades… from value to momentum . . . from stocks under $10 to ETF and option moves . . . from stocks that corporate insiders are buying up to companies that are about to report positive earnings surprises. You can even look inside exclusive portfolios that are normally closed to new investors.
Click here for Zacks' private trades >>